Intervention
Stereotactic Body Radiotherapy (SBRT)
ClinicalTrials.gov intervention label
Clinical trials
13 shownOral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLCNCT07754812 · 2026-06-25
RECRUITINGPSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPCNCT07649421 · 2026-09-15
NOT_YET_RECRUITINGNavigation Bronchoscopy Guided Microwave Ablation Versus SBRT in Early NSCLCNCT07722182 · 2026-08-10
NOT_YET_RECRUITINGA Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate CancerNCT05079698 · 2021-10-01
ACTIVE_NOT_RECRUITINGStudy of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate CancerNCT04262154 · 2020-03-03
ACTIVE_NOT_RECRUITINGEfficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)NCT03924869 · 2019-06-25
TERMINATEDProstate Boost Irradiation With Stereotactic Body RT (SBRT)NCT03380806 · 2019-01-01
UNKNOWNStereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms TumorsNCT02581384 · 2017-01-01
TERMINATEDFLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung CancerNCT02839265 · 2016-07-01
COMPLETEDLungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLCNCT01795521 · 2015-08-01
UNKNOWNStereotactic Body Radiotherapy Versus Conventional Radiotherapy in Medically-Inoperable Non-Small Lung Cancer PatientsNCT01968941 · 2014-05-07
COMPLETEDStereotactic Body Radiotherapy (SBRT) Versus Sublobar Resection for High-Risk Patients Non-Small Lung CancerNCT01622621 · 2012-05-01
TERMINATEDIrradiation of Large Lung Tumors or Two or More Lung Metastases SimultaneouslyNCT01543672 · 2011-11-22
COMPLETEDCommon conditions
Non-small Cell Lung Cancer2Prostate Cancer2Clear Cell Renal Cell Carcinoma1Ewing Sarcoma1Lung Cancer1Lung Cancer (NSCLC)1Lung Neoplasms1Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)1Metastatic Lung Cancer1Metastatic Prostate Cancer1Non-Rhabdomyosarcoma Soft Tissue Sarcoma, Nos1Non-small Cell Lung Cancer (NSCLC)1Non-small Cell Lung Cancer Stage I1Non-small Cell Lung Cancer Stage II1NSCLC (Non-small Cell Lung Cancer)1Osteosarcoma1Renal Tumor1Rhabdoid Tumor1Rhabdomyosarcoma1Sarcoma1Sarcoma, Ewing1Soft Tissue Sarcoma1Wilms Tumor1
Leading sponsors
Memorial Sloan Kettering Cancer Center2Chinese University of Hong Kong1Dana-Farber Cancer Institute1European Organisation for Research and Treatment of Cancer - EORTC1Juravinski Cancer Center1Mayo Clinic1Merck Sharp & Dohme LLC1Montefiore Medical Center1Ontario Clinical Oncology Group (OCOG)1Shanghai Pulmonary Hospital, Shanghai, China1The Netherlands Cancer Institute1West China Hospital1
Trial status mix
COMPLETED3
TERMINATED3
ACTIVE_NOT_RECRUITING2
NOT_YET_RECRUITING2
UNKNOWN2
RECRUITING1
Phase mix
PHASE29
PHASE13
PHASE32
PHASE41
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.